• New technology for the proteomic age (Nature publication)

    September 12, 2013 A leader in protein-based diagnostic tests, Biodesix is improving the precision of applying personalized medicine by advancing beyond the exploration of genes To the researchers at Biodesix, the genomic age is a rest stop along the road to even more precisely targeted therapies and applications. They are looking beyond genes and focusing on proteins. Biodesix, a ... Read more
  • Biodesix’s VeriStrat Test for Cancer Treatment Passes Phase 3 Trial (Xconomy)

    June 3, 2013 Biodesix, a Boulder, CO-based company that develops molecular diagnostic tests, said today that it has passed a key clinical trial that shows its VeriStrat test can give physicians a better idea of what to do next after the first round of treatment for non-small cell lung cancer has failed. The result of the trial, from the third and ... Read more
  • Putting Lung Cancer in the Bullseye (Breakthroughs)

    September 25, 2012 Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. She’s deep into researching targeted therapies for lung cancer so she can offer up better treatment options. The disease has been the leading cause of cancer deaths for a long time, but researchers like her are making some progress.  ... Read more
  • Biodesix Feels the Buzz at BIO2012 (FierceBiomarkers)

    July 26, 2012 Paul Beresford, vice president of business development and strategic marketing at Biodesix, spoke to FierceBiomarkers ahead of his appearance on the BIO2012 panel “Commercialization of Personalized Medicine: Stakeholders’ Recipe For Success.” So what is Biodesix’s own recipe for success? Keeping it collaborative and seeking validation, he explains. Biodesix’s business model is based on two strands–clinical diagnostics and ... Read more
  • A Test to Go With It (GenomeWeb)

    July 10, 2012 Personalized medicine promises to tailor treatments to patients’ diseases, so to determine whether a drug is suitable for a given patient, pharmaceutical companies are increasingly turning to companion diagnostic tests — tests that, by definition, are necessary to decide if a course of treatment is right for a particular patient. Many such companion tests are ... Read more
  • Charting a Course for Progress Institute of Medicine report calls for rigor and standardization (The Burrill Report)

    July 10, 2012 Some of the fastest evolving tools for evaluating the molecular and genetic underpinnings of disease are proving difficult to wield. Despite their great potential, it has been difficult to translate data generated through genomics, proteomics, and metabolomics into actual improvements in patient care.  In hopes of speeding that progress, The Institute of Medicine in March ... Read more
  • A Better Route for Diagnostics? (Drug Discovery & Development)

    June 12, 2012 From the moment of its inception, the Human Genome Project was expected to yield substantial benefits in diagnostics. But the genome is only part of the story. Equally important are the mRNA transcripts that carry out the genome’s orders, the proteins they encode, and ultimately, the metabolites upon which they act. Today, thanks to rapid ... Read more
  • Advances in Personalized Medicine for Lung Cancer (Science Daily)

    May 22, 2012 Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva. “A major goal of lung cancer treatment is to tailor the treatment to the individual,” says Dr Fiona Blackhall from The Christie ... Read more
  • Protein Test Found to Boost NSCLC Survival, Costs (MedPage Today)

    January 16, 2012 This study found that choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer (NSCLC). The four- to six-week survival advantage held up in a sensitivity analysis involving 10,000 simulations. Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in ... Read more
  • Trial Shows Biodesix Assay Predicts Breast Cancer Response to Femara (Genetic Engineering News)

    December 13, 2011 The use of Biodesix’ predictive cancer therapy assay VeriStrat has been validated in a Phase III trial originally carried out to evaluate GlaxoSmithKline’s Tykerb®/Tyverb® (lapatinib) as an addition to Novartis’ Femara® (letrozole) in breast cancer patients. Data from the trial demonstrated that VeriStrat could be used to identify a group of patients with worse progression-free survival (PFS) when treated with Femara alone, independent of Her2 ... Read more